𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice

✍ Scribed by J. M. Lord; T. W. Atkins; C. J. Bailey


Publisher
Springer
Year
1983
Tongue
English
Weight
575 KB
Volume
25
Category
Article
ISSN
0012-186X

No coin nor oath required. For personal study only.

✦ Synopsis


The effect of metformin on hepatocyte insulin receptor binding was examined in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice. In normal mice, chronic administration of metformin (60 mg X kg-1 X day-1 for 50 weeks) increased the number of low affinity receptors by 148%. During acute studies, metformin increased (30%) the number of low affinity receptors after 24 h. When metformin was withdrawn after treatment for 96 h, the number of low affinity receptors decreased, approaching control values by 48 h. In severely insulin resistant ob/ob mice, the concentrations of high and low affinity receptors were reduced by 60% and 27%, respectively. A high dose of metformin (240 mg X kg-1 X day-1 for 4 weeks) increased the concentration of high and low affinity receptors in ob/ob mice by 63% and 86%, respectively. However, the hypoglycaemic response to exogenous insulin was not altered. In streptozotocin-diabetic mice, the number of low affinity receptors was increased by 68% compared with normal mice. Metformin (60 mg X kg-1 X day-1 for 10 weeks) did not significantly alter the number of insulin receptors in streptozotocin-diabetic mice, but the hypoglycaemic response to exogenous insulin was improved by 94%. The results raise the possibility that metformin might affect post-receptor sites of insulin action independently of effects at the receptor level.


📜 SIMILAR VOLUMES


Comparison of the anti-diabetic effects
✍ Nigel Irwin; Paula L. McClean; Roslyn S. Cassidy; Finbarr P. M. O'Harte; Brian D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

## Abstract ## Background The two major incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are being actively explored as anti‐diabetic agents because they lower blood glucose through multiple mechanisms. The rapid inactivation of GIP and GLP‐